Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 45Neoplasms 44Multiple Myeloma 42Stomach Neoplasms 35Neoplasm Metastasis 32Leukemia, Myeloid, Acute 32Ovarian Neoplasms 31Lung Neoplasms 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Recurrence 25Small Cell Lung Carcinoma 21Brain Neoplasms 21Esophageal Neoplasms 20Colonic Neoplasms 20Uterine Cervical Neoplasms 19Lymphoma, Large B-Cell, Diffuse 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × beta-Thalassemia × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡